- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.03. | WuXi AppTec sells UK-US units, but annual results show foreign contracts continue despite China tensions | ||
| 25.03. | Overcoming regulatory challenges in sterile manufacturing | ||
| 25.03. | UKHSA unveils high-risk pathogen list to drive innovation | ||
| 25.03. | Trump tariffs drive pharma manufacturing to US but risk inflation and disruption | ||
| 25.03. | EMA to review GSK's Nucala for COPD treatment expansion | ||
| 25.03. | Sermonix and Regor to enhance breast cancer treatment options | ||
| 24.03. | Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry | ||
| 24.03. | Tempero secures $70m to advance addiction treatment candidate | ||
| 24.03. | Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge | ||
| 24.03. | Rising Sirturo resistance highlights urgent need for new TB therapies | ||
| 24.03. | Alberta partners Siemens and the Alberta Cancer Foundation | ||
| 24.03. | Augustine secures $85m to advance Charcot-Marie-Tooth candidate | ||
| 24.03. | FDA approves IND application for Everest's cancer vaccine | ||
| 24.03. | AstraZeneca to invest $2.5bn in R&D centre in China | ||
| 21.03. | China conditionally approves Hutchmed's Tazverik for follicular lymphoma | ||
| 21.03. | European agencies catch up with speedier regulatory pathways for CGTs in the US | ||
| 21.03. | Global funding cuts reversing decades of tuberculosis progress, WHO says | ||
| 21.03. | How to manage regulatory complexities with clinical trial data | ||
| 21.03. | Menarini to enhance BPDCN detection with VisualDx's link | ||
| 21.03. | FDA approves Johnson & Johnson's Tremfya to treat Crohn's disease | ||
| 20.03. | Servier and Black Diamond sign deal for solid tumours therapy | ||
| 20.03. | International Reference Pricing (IRP) 2024: A year in review | ||
| 20.03. | Roche's discontinued Alzheimer's drug shows signs of preventing onset | ||
| 20.03. | Pfizer sells 7.3% stake in Haleon for $3.3bn | ||
| 20.03. | Oxford BioTherapeutics and Roche link on antibody cancer treatments |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
